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Rett syndrome (RS) is a severe neurodevelopmental
disorder that contributes significantly to severe intellectual
disability in females worldwide. It is caused by mutations in
MECP2 in the majority of cases, but a proportion of
atypical cases may result from mutations in CDKL5,
particularly the early onset seizure variant. The relationship
between MECP2 and CDKL5, and whether they cause RS
through the same or different mechanisms is unknown, but
is worthy of investigation. Mutations in MECP2 appear to
give a growth disadvantage to both neuronal and
lymphoblast cells, often resulting in skewing of X
inactivation that may contribute to the large degree of
phenotypic variation. MeCP2 was originally thought to be
a global transcriptional repressor, but recent evidence
suggests that it may have a role in regulating neuronal
activity dependent expression of specific genes such as
Hairy2a in Xenopus and Bdnf in mouse and rat.
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R
ett syndrome (RS) was first described as a
clinical entity in the German literature in
1966.1 Hagberg and colleagues increased
awareness of the disorder in the English medical
literature in 1983 with a further description of
the condition in 35 girls with strikingly similar
clinical features of ‘‘progressive autism, loss of
purposeful hand movements, ataxia, and
acquired microcephaly’’.2 RS is now recognised
as a panethnic disorder, and presents an ever
widening clinical phenotype.3 The estimated
cumulative incidence of RS in Australia is 10
per 100 000 females by the age of 12 years4 and it
is considered to be the second most common
cause, after Down’s syndrome, of severe mental
retardation in females.5 RS is a severe neuro-
developmental disorder characterised by the
progressive loss of intellectual functioning, fine
and gross motor skills and communicative
abilities, deceleration of head growth, and the
development of stereotypic hand movements,
occurring after a period of normal development.
Girls with RS often develop seizures, a disturbed
breathing pattern with hyperventilation and
periodic apnoea, scoliosis, growth retardation,
and gait apraxia.2
The association of RS with mutations in the
methyl-CpG binding protein 2 gene (MECP2) was
recognised in 1999.6 The MeCP2 protein is
known to bind methylated CpG sequences and
recruit silencing complexes that lead to compac-
tion and silencing of surrounding chromatin. The
mechanism(s) by which MeCP2 dysfunction
causes RS remains somewhat of an enigma, but
recent advances in our knowledge of its precise
roles in neuronal and other cell types have gone a
long way towards clarifying this issue.
Nevertheless, diagnosis of RS remains a clinical
one, as a small proportion of clinically well
defined RS patients (,5–10%) do not appear to
have MECP2 mutations.
CLINICAL OVERVIEW
RS is characterised by a specific developmental
profile, with the diagnosis of RS being based on a
consistent constellation of clinical features and
the use of established diagnostic criteria.7 More
recently, refined diagnostic criteria have been
proposed to clarify previous ambiguities in
interpretation of clinical features8 (table 1, fig
1), and guidelines have been developed to aid
researchers in being more consistent in their
reporting of clinical features in RS patients.9
The diagnostic criteria for classical RS include
a normal prenatal and perinatal period with
normal developmental progress for the first
5–6 months of life. The birth head circumference
is normal with subsequent deceleration of
head growth, usually leading to microcephaly.
Between 3 months and 3 years there is reduction
or loss of acquired skills such as purposeful hand
function, vocalisation, and communication skills.
The hallmark of RS is the intense, sometimes
continuous, stereotypic hand movements, which
develop after the loss of purposeful hand move-
ments. Patterns consist of tortuous hand wring-
ing, hand washing, clapping, patting, or other
more bizarre hand automatisms, during waking
hours.5 A jerky truncal and or gait ataxia is
another prominent feature. Supportive diagnos-
tic criteria include breathing dysfunction, EEG
abnormalities, spasticity, peripheral vasomotor
disturbance, scoliosis, and growth retardation. It
has been suggested that the classical RS pheno-
type can be described as having a four stage
clinical evolution, and this has helped in
discussing the natural history of the disorder
with parents.10 According to the recently revised
criteria,8 the clinical diagnosis of RS is excluded
if there is evidence of a storage disorder,
retinopathy, cataract, or optic atrophy, an iden-
tifiable metabolic or neurodegenerative disorder,
an acquired neurological disorder, or evidence of
perinatal or postnatal brain injury. It must not be
Abbreviations: BDNF, brain derived neurotrophic factor;
CDKL5, cyclin dependent kinase-like 5; ISSX, infantile
spasms syndrome, X linked; MECP2, methyl-CpG binding
protein 2; MR, mental retardation; ORF, open reading
frame; RS, Rett syndrome; STK9, serine threonine kinase
9; XLRS, X linked retinoschisis
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forgotten that RS may occur coincidently with other
disorders,11 12 potentially delaying the diagnosis.
With increasing experience it has become clear that
females with RS may present with a much broader phenotype
than originally described. A number of variants have been
described, which may be more or less severe than the clinical
picture seen in classical RS.13 Although initially thought to be
a disorder exclusively affecting females, males with a Rett-
like phenotype have been reported occasionally, including
those who also have a 47XXY karyotype,14 males who are
mosaic for severe mutations,15 and males who may have
milder mutations.16 In addition, other non-RS phenotypes
have been associated with MECP2 mutations (see below).
Management
Medical management of RS is essentially symptomatic and
supportive. A multidisciplinary team approach is advocated,
aimed at maximising each patient’s abilities and facilitating
any skills that may be emerging. Management should include
psychosocial support for the families, development of an
appropriate education plan, and assessment of available
community resources. Parent support groups are crucial in
providing support for families. Pharmacological treatments
for RS have included L-carnitine, which may lead to an
improvement in patient wellbeing and quality of life,17–19
magnesium to reduce the episodes of hyperventilation,20 and
melatonin to improve sleep dysfunction.21 Evaluation of the
efficacy of these and other potential treatments on the
horizon will require carefully constructed clinical trials, using
validated instruments for measuring clinical improvements
and relevant biochemical markers.
Decreasing repetitive purposeless hand movements can be
achieved by the use of various arm restraints, such as soft
elbow splints, and are occasionally helpful in training specific
hand skills such as self feeding. These methods are also
helpful in decreasing agitation and self injurious behaviour.22
Feeding problems are common in RS.23 Several factors
contribute to this, including poor caloric intake secondary to
swallowing difficulties and immature chewing patterns, and
energy expenditure imbalances with calories used to sustain
motor activities at the expense of growth. Despite a voracious
appetite, some girls experience poor weight gain. This may be
because the majority of girls are unable to feed themselves,
and very few develop mature chewing patterns. A gastros-
tomy tube may be used as an alternate route to supplement
nutrition. Gastro-oesophageal reflux may respond to con-
servative medical treatment with anti-reflux agents, thick-
ened feeds, and positioning. Budden found that frequent
small feeds during the day with added carbohydrate foods
not only maintained growth and weight gain, but had a
Table 1 Revised diagnostic criteria for classical and variant RS. Derived from tables 3 and 4 in the paper by Hagberg et al.8
Necessary criteria Supportive criteria Exclusion criteria
Classical RS Apparently normal prenatal and
perinatal history
Breathing disturbances while awake
Bruxism
Organomegaly or other evidence of a
storage disorder
Psychomotor development normal
during the first 6 months (may be
delayed from birth)
Impaired sleeping pattern from early
infancy
Abnormal muscle tone accompanied
Retinopathy, cataract, or optic atrophy
History of perinatal or postnatal
brain damage
Normal head circumference at birth by muscle wasting and dystonia Identifiable inborn error of metabolism
Postnatal deceleration of head
growth (most individuals)
Abnormal muscle tone accompanied
by muscle wasting and dystonia
or neurodegenerative disorder
Acquired neurological disorder due to
Loss of purposeful hand skills
between 0.5–2.5 years
Peripheral vasomotor disturbances
Progressive scoliosis or kyphosis
severe infection or head trauma
Stereotypic hand movements Growth retardation
Evolving social withdrawal,
communication dysfunction, loss of
acquired speech, cognitive impairment
Hypotrophic small and cold feet
and/or hands
Impaired or deteriorating locomotion
Variant RS At least 3 of the 6 main criteria Breathing irregularities
At least 5 of the 11 supportive criteria Air swallowing or abdominal bloating
Main criteria Bruxism
Absence or reduction of hand skills Abnormal locomotion
Reduction or loss of speech
(including babble)
Scoliosis or kyphosis
Hand stereotypies Lower limb amyotrophy
Reduction or loss of
communication skills
Cold, discoloured feet, usually
hypotrophic
Deceleration of head growth
from early childhood
Sleep disturbances, including night
time screaming
Regression followed by recovery
of interaction
Inexplicable episodes of laughing or
screaming
Apparently diminished pain sensitivity






















Figure 1 Staging system for classical Rett syndrome. Derived from
Hagberg and Witt-Engerstrom.10
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definite influence on agitation and irritability in younger
girls.23
The majority of RS girls lose verbal expressive language,
although some retain some speech or single word expres-
sions. Alternative forms of communication that may be used
include communication boards, technical devices, and switch
activated systems. These are used for making choices and
facilitate environmental access. Some girls are also able to
communicate through eye pointing, gestures, body language,
and hand pointing.22 These abilities need to be recognised and
encouraged.
Seizure control is a common problem in the care of females
with RS. A major challenge in diagnosis may be differentiat-
ing seizures from the behavioural patterns often associated
with RS. Breathing irregularities such as breath holding and
hyperventilation, episodes of motor activity such as twitch-
ing, jerking, or trembling, or a cardiac arrhythmia associated
with a prolonged QT interval are most commonly confused
with seizures. Studies using prolonged video EEG polygraphic
monitoring indicate that the occurrence of seizures is
overestimated. Most episodes identified by parents represent
non-epileptic behavioural events. On the other hand, some
actual seizures may be unrecognised by parents or occur
during sleep.24 EEG telemetry and parental education may
assist in identifying true seizure events.
Prolonged heart rate corrected QT values have been
reported in association with RS.25 26 Prokinetic agents (such
as cisapride), antipsychotics (such as thioridazine), tricyclic
antidepressants (such as imipramine), anti-arrhythmics
(such as quinidine, sotolol, amiodarione), anaesthetic agents
(such as thiopental, succinylcholine), and antibiotics (such as
erythromycin, ketoconazole) should therefore be avoided
because of the possibility of precipitating electrocardiogram
QT abnormalities and cardiac arrhythmias.
Scoliosis is found in approximately 65% of girls with RS.
Some girls require bracing, while others require surgical
intervention.22 27 Increased tone in the Achilles tendon is one
of the earliest manifestations of onset of rigidity, usually
followed by toe walking. It is important to maintain
ambulation, and so bilateral ankle foot orthoses need to be
used to prevent foot deformities, maintain foot alignment,
and keep the heel cords lengthened. Physiotherapy is also
required to keep the Achilles tendons stretched.22
MECP2 MUTATIONS IN RS AND OTHER CLINICAL
PHENOTYPES
The MECP2 gene is located at q28 on the human X
chromosome, and has been demonstrated to undergo X
inactivation in mice and humans.28 29 It encodes a protein of
498 (MeCP2B or MeCP2a; encompassing exon 1 but not exon
2) or 486 amino acids (MeCP2A or MeCP2b; encompassing
part of exon 2 but not exon 1), depending on the use of
alternative splice variants,30 31 (figure 2A), with MeCP2B
being the predominant isoform in brain. MeCP2A may
predominate in other tissues, such as fibroblast and
lymphoblast cells.31 There are known MeCP2 orthologues in
rat, mouse, monkey, Xenopus, and zebrafish (http://mecp2.
chw.edu.au/mecp2/info/MECP2_homologues.shtml), suggest-
ing that MeCP2 has served important functions throughout
vertebrate evolution, although these may be different
between widely divergent species.
Apart from a nuclear localisation signal, MeCP2 has three
functional domains (figure 2B). The methyl-CpG binding
domain, at position 0–174, binds exclusively to symmetrically
methylated CpGs. The transcriptional repression domain, at
position 219–322, is able to recruit co-repressor complexes
that mediate repression through deacetylation of core
histones, with consequent compaction of DNA into hetero-
chromatin.32 33 MeCP2 interacts with either the Sin3A/HDACI
or Ski/NcoR/HDACII repression complexes to do this.34 In
addition, MeCP2 also has HDAC independent silencing
capabilities.35 The WW domain binding region, from residue
337 to the C terminus, specifically binds to group II WW
domains of splicing factors including formin binding protein
II and Huntington yeast protein C (HYPC).36 MeCP2 thus has
the capability to interpret methylated CpGs differently,
possibly leading to different downstream responses, depend-
ing on the context.
Following the first report of MECP2 mutations in RS
patients,6 there was intense mutation screening of cohorts of
patients, and attempts to draw phenotype–genotype correla-
tions, with conflicting results.37–43 Several mutation data-
bases have also been developed (http://homepages.ed.ac.uk/
skirmis/; http://mecp2.chw.edu.au/).44 There is some agree-
ment that missense mutations are generally milder than
nonsense mutations, that mutations in the methyl binding
domain are often more severe than those in the transcription
repression domain, and that skewing of X inactivation can
modulate the severity of the disorder. In addition, studies of a
number of patients with the same mutation have made it
possible to draw firm conclusions as to the severity of speci-
fic mutations.43 45 46 However, variation may still be seen
between patients with the same mutation and apparently
random X inactivation, suggesting that other mechanisms
may also modulate the clinical severity, with differences in
upstream regulators or downstream targets of MeCP2 being
possible candidates.
The association of skewing of X inactivation with RS has
long been a subject of debate. An increased incidence of
skewing has been reported by some authors,41 47–49 but not
others.50–54 Skewing has been investigated in a limited
number of regions in a small number of RS brain samples,55
and these authors found random inactivation in 10/10
samples that were informative for the assay. However, it
has been demonstrated that both lymphocytes56 and neuronal
cells57 expressing mutant MeCP2 are at an in vitro growth
disadvantage. In addition, two different MeCP2 null mouse
models showed uniform distribution of MeCP2 in the brains
of heterozygous females, but skewed X inactivation favouring






















Figure 2 (A) Structure of the MECP2 gene and mRNA (adapted from
Kriaucionis and Bird,30 and Mnatzakanian et al31). Alternative splicing
for the A (b) isoform is shown above the gene and for the B (a) isoform
below the gene. The B isoform has the highest expression in brain, and
mutations specific to this isoform are sufficient to cause RS.31 (B) Structure
of the B isoform MeCP2 protein sequence. The protein is 486 amino
acids in size. MBD, methyl-CpG binding domain; TRD, transcription
repression domain; NLS, nuclear localisation signal.
Rett syndrome update 3
www.jmedgenet.com
 on 18 September 2008 jmg.bmj.comDownloaded from 
regional skewing in the brains of mice carrying the common
308X mutation, and we have demonstrated that there may be
regional variation in human RS brains.61 Furthermore, it has
been demonstrated that skewing in the brains of mutant
mice correlates with the phenotypic outcome, with the
chance of manifestation of certain symptoms decreasing
with increasing expression of the wild type allele.57 These
studies, combined with previous studies of X inactivation in
RS patients, strongly suggest that skewing plays a significant
role in modulating phenotypic severity.
Prior to the identification of the MeCP2B (MeCP2a)
isoform, mutation detection efforts had focused on PCR
based approaches to screening exons 2, 3, and 4. More
recently, it has been recognised that up to 15% of apparently
MECP2 mutation negative individuals have large deletions
(spanning kilobases) that would be missed by this
approach.62–65 In addition, the identification of the new
MeCP2 isoform has raised the speculation that some
individuals may have mutations in exon 1,31 although in
our experience this appears to be an uncommon event
(unpublished observations).66 Using a combination of PCR
based screening approaches for the MECP2 coding regions
and one or other method to screen for large deletions, it has
been suggested that pathogenic MECP2 defects will be
identified in up to 90–95% of RS cases.63 A remaining
challenge is to identify the genetic defect in the remaining
5–10% of cases, with possible regions of interest including the
MECP2 promoter region, the blocks of highly conserved
sequence within the very large 39 untranslated region,67 or
novel genes (see below).68 69
Interestingly, the vast majority of single nucleotide
changes in the MECP2 gene are the result of CRT transitions
at CpG hotspots.41 70 71 The general restriction of RS to females
and the very low recurrence rate72 appear to be the result of a
large proportion of these mutations arising via spontaneous
deamination of 5-methylcytosine to thymine in the heavily
methylated male germ cells.73–75
A large degree of phenotypic variability is seen in both RS
patients and people with MECP2 mutations, ranging from
classical RS to normal individuals with protective skewing of
X inactivation. The phenotype associated with MECP2
mutations has broadened even further to include males with
severe neonatal encephalopathy,70 76, males from X linked
mental retardation pedigrees,77–81 PPM-X syndrome,82
Angelman syndrome,83 84 and infantile autism.85
FUNCTIONAL CONSEQUENCES OF MECP2
MUTATIONS
MeCP2 was initially thought to function as a global
transcriptional repressor, but the specifically neuronal pheno-
type associated with mutations, and the apparent lack of
global gene dysregulation in cell lines from RS patients,86 87
and in brains from human RS patients88 and RS mouse
models,87 do not support this suggestion.
Recent studies have begun to identify specific MeCP2
targets. In Xenopus, MeCP2 inhibits the expression of
xHairy2a, which itself is a target of the Notch/Delta signalling
pathway.89 With reduction of MeCP2 activity, xHairy2a
expression is increased, and this leads to inhibition of
primary neurogenesis.89 It will be interesting to study
whether MeCP2 plays a role in other Notch regulated aspects
of neuronal maturation, including dendritic branching,
which is known to be abnormal in the RS brain.
Studies of MeCP2 expression in primate prefrontal cortex
demonstrate increases during development, with expression
expanding from the deeper cortical layers and subplate in
110 day embryos, to robust expression throughout the
prefrontal cortex in adult monkeys.90 Moreover, increased
MeCP2 expression appears to be associated with neuronal
maturation, particularly in the hippocampus, cortex, and
cerebellum, the brain regions primarily affected in RS.91 92
These combined expression data suggest that MeCP2 has
specific functions in neuronal cells of the central nervous
system. Indeed, Aber et al93 demonstrated that MeCP2
localises both to the postsynaptic compartments of neuronal
cells and to the nucleus, suggesting that MeCP2 links the
regulation of transcription to synaptic activity.
Two recent papers have identified one possible MeCP2
target in this pathway in mammals.94 95 These authors found
that MeCP2 binds specifically to BDNF (brain derived
neurotrophic factor) promoter III in rat and promoter IV in
mouse, respectively, thereby repressing BDNF transcription in
resting neuronal cells. Membrane depolarisation of neuronal
cells led to calcium dependent phosphorylation and release of
MeCP2 (fig 3), suggesting that MeCP2 may regulate the
transcription of activity dependent genes in neuronal cells,94
which is important in synapse development and neuronal
plasticity.
Deletion of the C terminus of MECP2 encompassing the
WW domain binding region occurs commonly in RS patients,
and is associated with loss of binding to the splicing factors
FBP11 and HYPC.36 Preliminary evidence from our laboratory
suggests that cell lines carrying C terminal deletions may
shift towards recruiting smaller protein complexes on
binding unmethylated or partially methylated CpG rich
regions (data not shown). As these C terminal deletions do
not disrupt the MBD or the TRD, the pathogenesis in these
cases may be due to loss of the WW domain binding region,
and hence, loss of the proteins that normally interact with
this domain. These findings are yet to be confirmed in brain
and neuronal cells,36 but if they are, it raises the interesting
possibility that MeCP2 is involved in splicing, or that WW






Rat BDNF exon II
Mouse BDNF exon IV
MeCP2 is phosphorylated and





Rat BDNF exon III
PO3
Figure 3 Proposed model for MeCP2 regulated expression of BDNF. In
the resting neurone, MeCP2 binds the BDNF promoter, repressing its
activity. Following neuronal depolarisation, MeCP2 is phosphorylated,
perhaps by CDKL5, leading to its displacement from the BDNF promoter,
and thus allowing BDNF activation.
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CDKL5: A SECOND RS GENE?
The apparent lack of MECP2 mutations in a small proportion
of clinically well defined RS cases suggests the existence of at
least one other RS locus.41 71 Three recent reports,68 69 96
identified mutations in the gene for cyclin dependent
kinase-like 5 (CDKL5; OMIM #300203; also known as serine
threonine kinase 9 (STK9)) in patients who had been
diagnosed with atypical RS, supporting the existence of
genetic heterogeneity in RS. Somewhat similar to the MECP2
involvement in RS, mutations affecting CDKL5 appear to yield
clinical outcomes of varying severity. In addition to two
female patients with infantile spasms syndrome, X linked
(ISSX) and X;autosome translocations interrupting the
CDKL5 gene who were described by Kalscheuer et al,97 RS
patients with early onset seizures (seven cases), one girl with
an autistic disorder and intellectual disability, and a boy with
severe, early infantile onset neurological disorder have CDKL5
mutations.68 69 96 Additionally, one male patient with X linked
retinoschisis (XLRS) and a large deletion involving at least
the last coding exon of the CDKL5 gene had seizures, which
are otherwise not associated with XLRS.98 In this case it is
likely that the seizure phenotype was due to deletion of the
CDKL5 gene, but other gene contributions cannot be
excluded. In summary, there are currently nine published
(fig 4) and at least two unpublished RS cases (personal
communication: Dr H Archer, Dr J Evans, Professor A Clarke,
Department of Medical Genetics, University of Wales College
of Medicine, Cardiff, Wales) with mutations in, or involving
the CDKL5 gene. From among these, eight cases have been
diagnosed with the atypical, early seizure variant of RS,
suggesting that this may be the predominant phenotype
caused by CDKL5 mutations. Although still very tentative,
some speculations about the CDKL5 mutation genotype/
phenotype correlation can be drawn. While protein truncat-
ing mutations at the N terminal end97 cause a severe, early
onset phenotype of infantile spasms (phenotype overlapping
with that of ISSX as caused by the Aristaless (ARX) gene
mutations99), truncations more towards the C terminal end
cause atypical RS in girls, a severe neurological disorder in
boys, or autistic disorder with intellectual disability. Tissue
specific skewing of X inactivation, genetic background, and
as yet unknown environmental factors may contribute to the
phenotypic variability, as revealed in at least one case of
discordant monozygous twins.69
CDKL5 is a putative serine/threonine kinase of unknown
function.100 101 The connection between CDKL5 and MeCP2, if
there is one, and the mechanism by which they produce
overlapping phenotypes, will be important questions for
future studies to address. CDKL5 mutations appear to be
associated with severe, early onset seizures in particular, and
thus CDKL5 gene screening should be considered in atypical,
MECP2 negative RS cases. Whether ARX tested negative cases
with infantile spasms, or autism spectrum disorder cases
with intellectual disability and early onset seizures, should
also be considered remains to be investigated.
CONCLUSIONS
Recent advances in our knowledge of MECP2 splicing, its
specific targets, and the phenotypes and expression in
mutant mice have greatly contributed to our understanding
of the aetiology of RS. Studies in cell lines and mouse models
have confirmed the contribution that skewing of X inactiva-
tion can make to phenotypic variability.56–58 Identification of
Hairy2a89 and BDNF94 95 as bona fide targets of MeCP2 has
given glimpses of the mechanisms by which MECP2 muta-
tions lead to RS, and have enhanced the understanding of the
functions of MeCP2, which no longer appears to be the global
transcriptional repressor it was once assumed to be.102 Rather,
it may function to regulate the dynamic expression of
neuronal genes and the formation of new synaptic connec-
tions in response to electrical signalling, thereby explaining
the specifically neuronal phenotype associated with MECP2
mutations. Moreover, some of the phenotypic variability
observed in RS has been confirmed to result from genetic
heterogeneity. Several reports have identified mutations in
CDKL5 in specific atypical RS variants associated with early
onset seizures. It remains to be determined whether this or
other genes are responsible for a significant proportion of
atypical RS cases or other neurological phenotypes.
While much has been learnt about RS since its first des-
cription over 30 years ago, the pathogenesis of this important
and intriguing disorder is still not well understood. To fully
explain the RS disease phenotype will require the identification
of further gene targets forMeCP2 and CDKL5, particularly those
predominantly active in the central nervous system.
Such studies would greatly enhance the understanding
of normal brain development and function, and provide
opportunities for the development of targeted therapeutic
interventions for RS, possibly in the presymptomatic stage or
early in the evolution of the disorder.
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Figure 4 Exon structure of the CDKL5
(STK9) gene and its overlap with the
XLRS1 gene. Published mutations
involving the CDKL5 gene are indicated
with arrows. Mutations found in
patients with early seizure variant of RS
are underlined. The position of two
translocation breakpoints (associated
with ISSX) and a deletion involving both
XLRS1 and CDKL5 genes is also
indicated. All known exons of the
CDKL5 gene (solid boxes) and some of
the XLRS1 gene (empty boxes) are
indicated and numbered.
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